Panbela announces research agreement with johns hopkins university school of medicine

Minneapolis, feb. 10, 2021 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a research agreement with the johns hopkins university school of medicine. the collaboration is intended to focus on the further development of panbela's investigative agent sbp-101, including activity in cell lines outside of pancreatic cancer, biomarkers informing diagnostics and potential combination with checkpoint inhibitors.
PBLA Ratings Summary
PBLA Quant Ranking